Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 11/20 | 0.60 |
| ▸ | TNF | P01375 | 5/20 | 0.60 |
| ▸ | IL1B | P01584 | 4/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.49 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25647042 | 0.95 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25271278 | 0.88 | CRBN (0.61) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25647413 | 0.85 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25224659 | 0.84 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL26094453 | 0.83 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL31033528 | 0.83 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25647076 | 0.83 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25233562 | 0.82 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL3543582 | 0.82 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2030317 | 0.82 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |